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Background: Liver resection is a widely accepted treatment for hepatocellular carcinoma (HCC). Our previous
clinical study showed that the rate of palliative resection was 34.0% (1958-2008, 2754 of 8107). However, the
influence of palliative resection on tumor metastasis remains controversial. The present study was conducted to
evaluate the effect of palliative resection on residual HCC and to explore interventional approaches.
Methods: Palliative resection was done in an orthotopic nude mice model of HCC (MHCC97H) with high
metastatic potential. Tumor growth, invasion, metastasis, lifespan, and some molecular alterations were examined
in vivo and in vitro. Mice that underwent palliative resection were treated with the Chinese herbal compound
“Songyou Yin,” interferon-alfa-1b (IFN-a), or their combination to assess their effects.
Results: In the palliative resection group, the number of lung metastatic nodules increased markedly as compared
to the sham operation group (14.3 ± 4.7 versus 8.7 ± 3.6, P < 0.05); tumor matrix metalloproteinase 2 (MMP2)
activity was elevated by 1.4-fold, with up-regulation of vascular endothelial growth factor (VEGF) and down-
regulation of tissue inhibitor of metalloproteinase 2 (TIMP2). The sera of mice undergoing palliative resection
significantly enhanced cell invasiveness by 1.3-fold. After treatment, tumor volume was 1205.2 ± 581.3 mm
3, 724.9
± 337.6 mm
3, 507.6 ± 367.0 mm
3, and 245.3 ± 181.2 mm
3 in the control, “Songyou Yin,” IFN-a, and combination
groups, respectively. The combined therapy noticeably decreased the MMP2/TIMP2 ratio and prolonged the
lifespan by 42.2%. Moreover, a significant (P < 0.001) reduction of microvessel density was found: 43.6 ± 8.5, 34.5 ±
5.9, 23.5 ± 5.6, and 18.2 ± 8.0 in the control and treatment groups, respectively.
Conclusion: Palliative resection-stimulated HCC metastasis may occur, in part, by up-regulation of VEGF and
MMP2/TIMP2. “Songyou Yin” reinforced the ability of IFN-a to inhibit the metastasis-enhancing potential induced
by palliative resection, which indicated its potential postoperative use in patients with HCC.
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Hepatocellular carcinoma (HCC) is the third most com-
mon cause of cancer-related deaths worldwide [1]. Liver
resection is a widely accepted treatment modality for HCC;
at the authors’ institution, 53 patients with HCC with a 20-
year survival all underwent curative resection [2]. However,
the influence of liver resection on tumor growth and
metastasis remains controversial. Increasing numbers of
reports indicate that partial hepatectomy accelerates tumor
growth and stimulates tumor metastasis [3-7], although
one report claimed that major hepatic resection may sup-
press the growth of tumors remaining in the residual liver
[8]. Another report indicated that hepatectomy prolongs
survival of mice with induced liver metastases [9]. Finally, a
report demonstrated that surgical therapy is associated
with improved survival in patients with HCC [10].
Data from authors’ institution (1958-2008, unpub-
lished) revealed that the 5-year survival after palliative
HCC resection (30.0%, n = 2754) was much lower than
that following curative resection (52.6%, n = 5353). The
clinical observation that patients with HCC receiving
palliative resection (with grossly identified residual can-
cer) experienced dramatically increased metastases
implies that palliative resection may enhance the meta-
static potential of HCC, which is poorly understood to
the best of our knowledge. Therefore, this study aimed
to verify whether palliative resection enhances invasion
and metastatic potential of residual HCC and to explore
a novel approach for therapeutic intervention.
An orthotopic human HCC model in nude mice with
high metastatic potential, which was established at the
authors’ institution, was used [11-13]. Our previous
study showed that interferon-alfa-1b (IFN-a) [14] and
the herbal extract “Songyou Yin [15]“ (SYY) inhibit
HCC growth, metastasis, and recurrence and prolong
survival in the nude mice model system. Consequently,
these two agents were used for this interventional study.
Methods
Animals
Male athymic BALB/c nu/nu mice, weighing 18-20 g at
5 weeks of age, were obtained from the Shanghai Insti-
tute of Materia Medica, Chinese Academy of Science.
All mice were handled according to the recommenda-
tions of the National Institutes of Health Guidelines for
Care and Use of Laboratory Animals. The experimental
protocol was approved by the Shanghai Medical Experi-
mental Animal Care Committee.
HCC cell line and metastatic orthotopic tumor model in
nude mice
At the authors’ institution, a stepwise metastatic human
HCC model system was established, which included a
metastatic HCC model in nude mice LCI-D20 [11], an
HCC cell line MHCC97 with high metastatic potential
that originated from LCI-D20 tumor [12], and cell clone
MHCC97H from its parent MHCC97, with a lung meta-
static rate up to 100% using orthotopic inoculation [13].
Human HCC tumor models produced by MHCC97H
were established in nude mice by orthotopic inoculation,
as described previously [15]. The MHCC97H cells were
maintained in Dulbecco modified Eagle medium
(DMEM, Gibco-BRL, Gaithersburg, MD) without any
antibiotic. HCC cell lines of HCCLM3 with higher inva-
siveness and HCC7721, HCC7402, and Hep3B with very
low invasiveness were also prepared.
Drugs
The Chinese herbal medicine formula “Songyou Yin”
(SYY), a dietary component authorized by the Chinese
State Food and Drug Administration (Grant No.
G20070160), was originally designed to promote vital
energy and to be considered as a nontoxic therapeutic
supplement for cancer patients [15]. The mixture
includes five Chinese medicinal herbal extracts, whose
proportions (w/w) are as follows: Salvia miltiorrhiza
Bge., 14.3%; Astragalus membranaceus Bge., 14.3%;
Lycium barbarum L., 23.8%; Crataegus pinnatifida Bge.,
23.8%; and Trionyx sinensis Wiegmann, 23.8% (all from
China). The ethanol extract was prepared as follows:
The dried and pulverized medicinal herbs were mixed
together, and each batch was poached twice for a total
o f3h ,t h e nf i l t r a t e d ,c o n c e n t r a t e d ,a n ds o a k e dw i t h
ethanol for 12 h. Finally, SYY, with the level of relative
density 1.36 (60°-80°C), was obtained and stored at 4°C
before application in experiments. The SYY used in the
in vitro and in vivo studies, with the same batch number
(#060601), was produced by the Caitong Detang Chinese
Traditional Medicine Pharmaceutical Factory, Shanghai,
China. A 120-mg/mL sterilized SYY by two filtrations
was prepared and then diluted cell culture medium or
distilled water for further use. High-performance liquid
chromatography (HPLC) fingerprinting of SYY and its
five characteristic components was carried out by the
Shanghai Institute of Materia Medica (SIMM), Chinese
Academy of Sciences (CAS), China. The compound was
diluted with distilled water for further use, which inhi-
bits HCC cell lines MHCC97H with high invasive
potential and Hep3B cells with very low invasiveness in
vitro and inhibits HCC growth and metastasis in vivo
[15]. Recombinant IFN-a (Sinogen, Kexing Bioproduct
Company Ltd, Shenzhen, P.R. China) inhibits HCC,
which may be attributable to anti-angiogenesis [14,16].
Mice grouping and treatment
This study comprised 120 nude mice. In the first experi-
ment, 48 nude mice bearing HCC xenografts were ran-
domized into two groups 14 days after orthotopic
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resection group of mice undergoing partial HCC resec-
tion with preservation of 2 mm tumor [17] and a sham
operation group (control) of mice having only exposure
of the liver but no resection. In the second experiment,
another 72 nude mice (14 days after orthotopic implan-
tation) undergoing palliative resection were randomized
into four groups according to the different therapies (18
mice/group). Therapy started on day 2 after palliative
resection.
Control group mice each received 0.3 mL of distilled
w a t e rv i at h eo r a lg a v a g em e t h o do n c ead a ya n dw e r e
injected with sterile saline water (NS, 0.1 mL, subcuta-
neously) daily for 5 consecutive weeks 24 hours after
resection.
Each mouse in the SYY group received 0.3 mL of
“Songyou Yin” (3.6 g/kg/d/mouse) via the oral gavage
method [15] and NS, 0.1 mL, subcutaneously daily.
T h em i c ei nt h eI F N - a group received 0.3 mL of distilled
water via the oral gavage method and 0.1 mL of IFN-a (7.5
×1 0
6 U/kg/d/mouse), subcutaneously daily [14].
Finally, the SYY + IFN-a group received the combined
therapy with “Songyou Yin” and IFN-a as described for
the groups given each agent alone.
Parameters observed
In the first experiment, 6 mice of each group were
humanely killed by cervical dislocation 35 days after pal-
liative resection to detect pulmonary metastasis. The
remaining mice (18/group) were kept alive and their
lifespan was determined starting from the day of resec-
tion; the rate of prolonged life was calculated as done
previously [15]. The in situ activities of membrane type
1-matrix metalloproteinase (MT1-MMP), matrix metal-
loproteinase 2 (MMP2), and protein levels of MMP2,
tissue inhibitor of metalloproteinase 2 (TIMP2), vascular
endothelial growth factor (VEGF), and endostatin in the
grown tumors obtained from the implantation sites
were determined.
In the second experiment, daily general observations
and weekly body weights (BWs) of the mice were
recorded; 6 mice from each group were humanely killed
48 hours after the final treatment. Tumor size was mea-
sured with calipers and volume was estimated by the
formula V =L×H×W×0 . 5 2 3 6 ;t h et u m o ri n h i b i t i o n
rate was calculated [15]. The remaining 12 mice of each
group were maintained on the designated therapies until
death to determine their lifespan. Lung metastases,
MMP2 activity, protein levels of MMP2, TIMP2, and
VEGF, and microvessel density (MVD) were determined.
Samples prepared
Serum, lung tissues, tumor tissues, and their protein
extracts were harvested for in vitro and in vivo studies.
In vitro invasion and migration assays
The cells of MHCC97H, HCCLM3, HCC7721,
HCC7402, and Hep3B treated with serum from killed
mice and cell culture medium supplemented with 10%
human AB serum (control) for 72 hours were added to
the upper chamber (100 μLD M E M ,5×1 0
4 cells/well)
and 600 μL conditioned medium was added to the
lower chamber. The invaded cells were fixed with
methanol and stained with crystal violet solution after
a 24-hour incubation. The migration assay was similar
to the invasion assay, only without Matrigel. The
results were expressed as the number of penetrated
cells under microscope at ×200 magnification on five
random fields and were presented as means ± SD of
three assays [13].
Hematoxylin and eosin stains
Paraffin blocks of 10% buffered formalin-fixed samples
of tumor and lung tissues were prepared, serial sections
were cut at 5 μm, and pulmonary metastatic nodules
were verified with hematoxylin and eosin stain [18].
MT1-MMP activity assay
T h eM T 1 - M M Pa c t i v i t ya s s a yk i t( A m e r s h a mB i o s -
ciences, Buckinghamshire, UK) was used to detect active
endogenous MT1-MMP in tissue extracts with analytical
sensitivity of 0.7 ng/mL. The resultant color was read at
405 nm using an automated microplate reader (BioTek
Instrument, Winooski, VT). The concentration of active
MT1-MMP in the samples was determined by interpola-
tion from a standard curve.
Gelatin zymography assay
MMP2 activity in tumor tissue lysate was measured via
Gelatin zymography assay [15]. The MMP activity was
visualized as white proteolysis bands against the gel
stained with Coomassie blue. The molecular weights of
these bands indicating MMP2 activity were determined
by molecular weight standards (Bio-Rad Laboratories,
Hercules, CA). The relative MMP activity was quanti-
tated by scanning the zymogram photograph on a gel
documentation and analysis system (Alphalmager 2000,
Alpha Innotech, San Leandro, CA). The area and optical
density of each band was calculated and normalized by
its own internal control; the digitized data of photo-
graphs presenting MMP2 activities in the control group
were considered as 100%.
Enzyme-linked immunosorbent assay
Protein levels of MMP2, TIMP2, VEGF, and endostatin
in tumor extracts were measured via commercial avail-
able MMP2 (R&D Systems, Minneapolis, MN), TIMP2
(Amersham Biosciences, Buckinghamshire, UK), VEGF
enzyme-linked immunosorbent assay (ELISA; R&D
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International, Temecula, CA) kits. The mean of mini-
mum detectable dose of MMP2, TIMP2, VEGF, and
endostatin is 0.16 ng/mL, 3.2 ng/mL, 5 pg/mL, and 1.95
ng/mL, respectively. Absorbance was measured at 450
nm, using a microplate spectrophotometer with the cor-
rection wavelength of 570 nm. The assays were con-
ducted in triplicate.
MMP2 activity detected by ELISA
MMP2 activity was quantitated with a human MMP2
Activity ELISA System (Amersham Pharmacia Biotech,
Piscataway, NJ) according to the manufacturer’s instruc-
tions. The plate was read at 450 nm in a SPECTRAmax
250 Microplate Spectrophotometer (Molecular Devices,
Sunnyvale, CA). The assays were conducted in triplicate.
Immunohistochemistry assay
MVD (using CD34 immunostaining) was counted [19].
All slides were independently assessed by two board-cer-
tified pathologists who were blinded to the experiment.
Any difference in the microvessel count was resolved by
consensus.
Statistical analysis
Data were analyzed by the statistical SAS software pack-
age (SAS 8.2) using ANOVAs, Student t test, and
Kaplan-Meier method (log-rank test). All continuous
variables were expressed as means ± SD or means ± SE.
Statistical significance was set at P < 0.05.
Results
Palliative resection prolongs survival but increases lung
metastases in nude mice with HCC
Increased pulmonary metastases were found in the pal-
liative resection group (Figure 1A, left) as compared to
the control (Figure 1A, right). The number of lung
metastatic nodules was 14.3 ± 4.7 versus 8.7 ± 3.6 (P <
0.05, Figure 1B). However, the lifespan was longer in the
palliative resection group compared with that in the
control group (60.8 ± 2.7 d versus 51.3 ± 1.4 d, means ±
SE, P < 0.05).
We found that cells (MHCC97H) treated with serum
from the palliative resection group (Figure 1C, left)
presented the most invasive potential through Matrigel
as compared to cells in controls (Figure 1C, right),
with invasive ability increased by 25.7% (46.9/37.3, 1.3-
fold, P < 0.05, Figure 1D), which was intervalidated by
several HCC cell lines (HCCLM3, HCC7721,
HCC7402, and Hep3B). However, no significant differ-
ences were found in migration capacity of treated cells
among groups.
Palliative resection enhances MMP2 activity, elevates
tumor protein levels of MMP2 and VEGF, and down-
regulates TIMP2 in situ
Gelatin zymography assays clearly showed that tumor
MMP2 activity was stronger in the palliative resection
group (Figure 2A1); the normalized optical density of
the band presenting MMP2 activity was significantly ele-
vated (1.4-fold, P < 0.01, Figure 2A2), in accord with up-
regulation of the MMP2 protein level in the palliative
resection group, that is, 73.7 ± 8.0 ng/mg versus 57.9 ±
10.1 ng/mg (P < 0.01, Figure 2A3). TIMP2 was down-
regulated with reductions in TIMP2 levels to 15.6% of
control levels (P < 0.05, Figure 2B). Tumor VEGF levels
were also up-regulated by palliative resection, being
185.7 ± 13.6 pg/mg versus 164.5 ± 12.5 pg/mg (P <
0.05, Figure 2C). However, the alteration of activated
tumor MT1-MMP and endostatin levels did not reach
statistical significance between the two groups.
The combined therapy averts cancer-related BW loss and
reinforces antitumor effects in nude mice model
SYY inhibited the BW loss, IFN-a was not obviously
related to the BW loss, but the combined therapy
noticeably minimized the BWl o s s ,w i t ht h em a x i m u m
statistical difference of BW among groups observed at
the fifth week after treatment (Figure 3A). Tumor
volumes in the control, SYY, IFN-a,a n dS Y Y+I F N - a
groups were 1205.2 ± 581.3 mm
3, 724.9 ± 337.6 mm
3,
507.6 ± 367.0 mm
3, and 245.3 ± 181.2 mm
3, respectively
(P < 0.001, for the SYY + IFN-a g r o u pc o m p a r e dw i t h
control, Figure 3B1,2), with tumor inhibition rates of
39.9% (SYY group), 57.9% (IFN-a group), and 79.6%
(SYY + IFN-a group). At the end of the fifth week, the
mean number of lung metastatic nodules was reduced
by 12.3%, 46.4%, and 67.4%, respectively, compared to
the control (Figure 3C). The lifespan was significantly
extended in treatment groups( F i g u r e3 D ) ,a n dt h er a t e
of prolonged life was 42.2% in the SYY + IFN-a group.
Inhibitory effect of therapies correlates to the inhibition
of MMP2 and VEGF
Our data revealed that both tumor MMP2 activity (Fig-
ure 4A1) and MMP2 (Figure 4A2) and VEGF (Figure
4C) protein levels were significantly down-regulated in
treatment groups, whereas TIMP2 (Figure 4B) levels
were up-regulated when compared to the controls.
According to the inhibitory effects of SYY and IFN-a,
we found that SYY was more effective on MMP2 (Figure
4A1,2), IFN-a was more effective on VEGF (Figure 4C),
and the combined therapy was more effective than any
agent alone. On the other hand, tumor MVD (Figure
4D1) decreased in the treated groups, being 34.5 ± 5.9,
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Page 4 of 9Figure 1 Difference in tumor invasion and metastasis. (A) The representative pulmonary metastatic nodules (arrows, original magnification,
×400). (B) The difference in lung metastasis (P < 0.05). (C) The penetrated cells (original magnification, ×200) treated by resection mice serum
(left) was higher than that of control (right), bar, 50 μm. (D) The difference in invasiveness (P < 0.05). The bars indicate the means ± SD.
Figure 2 Molecular alterations. (A10 Gelatin zymography assay showed palliative resection activated MMP2. M, size marker; P, positive control.
(A2) The percentage of MMP2 activity was elevated 1.4-fold as compared with control (P < 0.01). (A3) Palliative resection up-regulated the tumor
MMP2 level (P < 0.01). (B) Palliative resection down-regulated tumor the TIMP2 level (P < 0.05). (C) Palliative resection up-regulated tumor the
VEGF level (P < 0.05). The bars indicate the means ± SD.
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Page 5 of 923.5 ± 5.6, and 18.2 ± 8.0, respectively, as compared to
control (43.6 ± 8.5, P < 0.001, Figure 4D2).
No animal experienced therapy-related side effects,
BW loss of > 10%, anemia, neutropenia, thrombocytope-
nia, or abnormal serum transaminases after the treat-
ment regimen in this study (data not shown).
Discussion
Hepatectomy is a standard treatment for patients with
HCC [2,10]. However, even in patients undergoing cura-
tive resection, the procedure is only potentially curative
due to the existence of tumor cells or clinically unde-
tectable residual intrahepatic lesions [2,3]. Our clinical
observation showed that after palliative resection the
patients experienced dramatically increased metastases
without systemically effective treatments from the onco-
logic standpoint. However, several studies have demon-
strated survival benefits from palliative liver resection
[20-23]. Thus, the effectiveness of palliative resection for
HCC remains controversial. This study was designed to
evaluate the progression of residual tumor after pallia-
tive resection and to explore an interventional approach
in a high metastatic human HCC model system that has
been successfully used for studies of HCC-related inva-
sion, metastasis [23], and screening of therapeutic agents
for HCC [14,15,18,24].
Palliative resection has been applied to treat HCC and
produced marked survival benefits when combined with




0.001 compared with control at the end of 5 weeks of treatment. (B1) Tumor volumes. Tumor volumes in the control, SYY, IFN-a, and SYY + IFN-
a groups were 1205.2 ± 581.3 mm
3, 724.9 ± 337.6 mm
3, 507.6 ± 367.0 mm
3, and 245.3 ± 181.2 mm
3, respectively. *P < 0.05, †P < 0.01, ‡P <
0.001 compared with control. (B2) Tumors in different groups with decreasing tendency. Tumor inhibition rate in 4 groups was 39.9% (SYY
group), 57.9% (IFN-a group), and 79.6% (SYY + IFN-a group), respectively. (C) The mean number of lung metastatic nodules in 4 groups. Six
mice from each group were humanely killed 48 hours after the final treatment. Paraffin blocks of 10% buffered formalin-fixed samples of lung
tissues were prepared, serial sections were cut at 5 μm, and pulmonary metastatic nodules were verified with hematoxylin and eosin stain. *P >
0.05, †P < 0.05, ‡P < 0.01 compared with control. (D) Survival curves among groups. The remaining 12 mice of each group were maintained on
the designated therapies until death to determine their lifespan.
aP < 0.05,
bP < 0.01,
cP < 0.001 compared with control. The bars indicate the
means ± SD.
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Page 6 of 9adjunct IFN-a/5-fluorouracil therapy [21,22]. It has been
postulated that the survival prolongation after palliative
resection may be partially due to tumor-debulking sur-
gery [21]. In this study, therefore, we investigated the
benefit from palliative resection in nude mice bearing
human HCC and found the lifespan was 60.8 ± 2.7 days
in palliative resection compared with 51.3 ± 1.4 days in
controls. Our result was consistent with previous reports
[21,22], which implied that patients with HCC could
benefit from palliative resection. In contrast, some stu-
dies have reported that partial hepatectomy accelerates
tumor growth and stimulates tumor metastasis [3-7].
Our experimental research revealed that palliative resec-
tion is followed by acceleration of metastatic processes
in the lungs. The increased pulmonary metastatic
nodules were found in the palliative resection group
(14.3 ± 4.7) compared to controls (8.7 ± 3.6), which
may be partially due to breakdown of tumor MMP2/
TIMP2 balance and in situ up-regulation of VEGF that
was consistent with a recent report that confirmed
increased VEGF transcription in residual HCC after
hepatectomy in a small animal model [25].
The higher ratio of MMP/TIMP has been related to
a poorer prognosis in HCC [26]. Our data revealed
that palliative resection activated MMP2 and down-
regulated TIMP2. Lower TIMP2 levels might cause
MMP2 activation, which resulted in degradation of the
extracellular matrix and increased angiogenesis. VEGF,
a potent stimulator of tumor angiogenesis, is believed
to have a major role in HCC angiogenesis, growth, and
metastasis. In this study, we found palliative liver
resection elevated tumor VEGF levels markedly, in
accordance with the literature [25]. The alteration of
endostatin (a potent angiogenesis inhibitor) and MT1-
MMP (an activator of MMP2) was minor, which indi-
cated that elevated tumor VEGF and increased MMP2
activity were not directly due to endostatin and MT1-
MMP, whose detailed molecular mechanism remains
to be elucidated.
In most studies, palliative resection for HCC was com-
bined with chemotherapy or biotherapy, such as IFN-a
[21,22]. Our previous studies revealed that IFN-a inhib-
ited HCC and extended the lifespan of mice and could
be attributed to anti-angiogenesis [14,16]; SYY directly
down-regulated MMP2 and VEGF and inhibited HCC
growth and metastasis [15]. Others also reported that
herbal medicine could inhibit the growth of MHCC97H
cells used in this study [27] and could inhibit the inva-
siveness potential of HCC cells via MMP2 inhibition
[28]. Based on our in vitro and in vivo studies, we con-
s i d e r e dt h a ti n h i b i t i o no ft h em e t a s t a s i s - e n h a n c i n g
effects due to dysregulation of MMP2/TIMP2 and
VEGF might further improve operative efficacy in
patients with HCC. Fortunately, the study showed that
Figure 4 Detection of VEGF, MMP2, TIMP2, and MVD. (A1) Tumor MMP2 activities. *P < 0.05, †P < 0.01 compared with control. (A2) Tumor
MMP2 levels. *P < 0.05, †P < 0.01 compared with control. (B) Tumor TIMP2 levels. *P < 0.01, †P < 0.001 compared with control. (C) Tumor VEGF
levels. *P < 0.05, †P < 0.01, ‡P < 0.001 compared with control. (D1) Representative CD34 immunostained intratumoral microvessels (original
magnification, ×200) in control group (left) and in the SYY + IFN-a group (right), bar, 50 μm. (D2) Tumor microvessel density (MVD). *P < 0.001
compared with control. The bars indicate the means ± SD.
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tive than any single agent on residual HCC following
palliative resection. This inhibitory effect of combined
therapy on progression of preexisting HCC was partially
associated with a decreased VEGF level and lower
MVD, which is in keeping with recent experimental evi-
dence that growth of small nests of cells can be stunted
by a variety of agents that have the common ability to
inhibit angiogenesis [29]. Moreover, in our study, the
side effects of therapy in mice were well tolerated
[14,15]. The weight changes in mice observed in this
research showed that SSY and the combined therapy
noticeably minimized BW loss at the fifth week after
treatment, which suggested that we should administer
herbal medicine for a long period. Consequently, more
attention should be paid to the active role of Chinese
herbal medications in combination therapy for patients
with HCC [30].
We are also aware of some limitations in our study.
First, we could not sufficiently elucidate the exact
mechanism of the metastasis-enhancing potential of
residual tumor. Further basic research for the stimulat-
ing effect is needed. Second, we did not offer a detailed
explanation for how SYY reinforced IFN-a to inhibit
HCC. Third, because the study used nude mice the abil-
ity to provide robust evidence is limited. Therefore,
large-scale, multicenter, placebo-controlled, and pro-
spective studies are needed to test our results. Despite
these limitations, we believe that the current study pro-
vides preliminary and powerful data to support future
evaluation of SYY in combination with IFN-a for HCC
in a large cohort, randomized clinical trial that has been
performed in Zhongshan Hospital of Fudan University,
Shanghai, PR China.
In summary, palliative resection induced the metasta-
sis-enhancing potential of residual HCC via breakdown
of the MMP2/TIMP2 balance and up-regulation of
VEGF, but the precise mechanism of this stimulating
effect remains to be elucidated. Combination therapy
with SYY plus IFN-a, by regulating the MMP2/TIMP2
ratio and VEGF expression, could be an effective thera-
peutic strategy to reverse the tumor-enhancing effect
derived from hepatectomy. The results indicate the
potential use of this therapy to improve the postopera-
tive prognosis of patients with HCC.
Conclusions
This study showed that palliative resection-accelerated
HCC metastasis may be attributed, in part, to up-regula-
tion of VEGF and MMP2/TIMP2; SYY reinforced IFN-a
to inhibit the metastasis-enhancing potential. Therefore,
the combined therapy of SYY plus IFN-a m a yb eu s e d
after hepatectomy for patients with HCC.
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